Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels
- 187 Downloads
Experimental studies disrupting sleep and epidemiologic studies of short sleep durations indicate the importance of deeper and longer sleep for cardiometabolic health. We examined the potential beneficial effects of lengthening the first uninterrupted sleep period (FUSP) on blood glucose. Long-term data (≥3 months of treatment) were derived from three clinical trials, testing low-dose (10–100 µg) melt formulations of desmopressin in 841 male and female nocturia patients (90 % of which had nocturnal polyuria). We performed post hoc multiple regression with non-fasting blood glucose as dependent variable and the following potential covariates/factors: time-averaged change of FUSP since baseline, age, gender, race, ethnicity, baseline glucose, baseline weight, change in weight, patient metabolic status (normal, metabolic syndrome, type II diabetes), dose, follow-up interval, and time of random glucose sampling. Increases in FUSP resulted in statistically significant reductions in blood glucose (p = 0.0131), even after controlling for all remaining covariates. Per hour increase in time to first void was associated with glucose decreases of 1.6 mg/dL. This association was more pronounced in patients with increased baseline glucose levels (test of baseline glucose by FUSP change interaction: p < 0.0001). Next to FUSP change, other statistically significant confounding factors/covariates also associated with glucose changes were gender, ethnicity, metabolic subgroup, and baseline glucose. These analyses indicate that delaying time to first void may have beneficial effects on reducing blood glucose in nocturia patients. These data are among the first to suggest that improving sleep may have salutary effects on a cardiometabolic measure.
KeywordsSleep disturbance Metabolic syndrome Blood glucose
Kristian Vinter Juul, Egbert van der Meulen, and Jens Peter Nørgaard are employees of Ferring Pharmaceuticals. Donald Bliwise is a Consultant to Ferring Pharmaceuticals. This study was funded by a Grant by Ferring Pharmaceuticals.
KVJ researched data, contributed to discussion, and wrote manuscript. NJ contributed discussion and reviewed/edited manuscript. DLB researched data, contributed to discussion, and wrote manuscript. EAvdM researched and analyzed data and contributed to discussion. JPN wrote manuscript reviewed/edited manuscript and contributed to discussion.
- 6.J.O. Clausen, K. Borch-Johnsen, H. Ibsen, R.N. Bergman, P. Houggard, K. Winther, O. Pedersen, Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. J. Clin. Invest. 98, 1195–1209 (1996)CrossRefPubMedPubMedCentralGoogle Scholar
- 8.J. Cedernaes, L. Lampola, E.K. Axelsson, L. Liethof, S. Hassanzadeh, A. Yeganeh, J.E. Broman, H.B. Schioth, C. Benedict, A single night of partial sleep loss impairs fasting insulin sensitivity but does not affect cephalic phase insulin release in young men. J. Sleep Res. (2015). doi: 10.1111/jsr.12340 Google Scholar
- 9.E. Donga, M. van Dijk, J.G. van Dijk, N.R. Biermasz, G.J. Lammers, K.W. van Kralingen, E.P. Corssmit, J.A. Romijn, A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J. Clin. Endocrinol. Metab. 95, 2963–2968 (2010)CrossRefPubMedGoogle Scholar
- 13.P.K. Sand, R.R. Dmochowski, J. Reddy, E.A. van der Meulen, Efficacy and safety of low-dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J. Urol. 190, 958–964 (2013)CrossRefPubMedGoogle Scholar
- 14.J.P. Weiss, S. Herschorn, C.D. Albei, E.A. van der Meulen, Efficacy and safety of low-dose desmopressin orally disintegrating tablet in men with nocturia: results of a multi-center, randomized, double-blind, placebo-controlled, parallel-group study. J. Urol. 190, 965–972 (2013)CrossRefPubMedGoogle Scholar
- 16.P.L. Flom, D.L. Cassell, Stopping stepwise: why stepwise and similar selection methods are bad, and what you should use. Proceedings of the 20th Annual NorthEast SAS Users Group and Proceedings of the SAS Global Forum, 361 (2008) http://www.lexjansen.com/pnwsug/2008/DavidCassell-StoppingStepwise.pdf Accessed 1 Feb 2016
- 20.J.E. Gangwisch, S.B. Heymsfield, B. Boden-Albala, R.M. Buijs, F. Kreier, T.G. Pickering, A.G. Rundle, G.K. Zammit, D. Malaspina, Sleep duration as a risk factor for diabetes incidence in a large US sample. Sleep 30, 596–603 (2007)Google Scholar
- 36.O. Yokoyama, O. Yamaguchi, H. Kakizaki, N. Itoh, T. Yokota, H. Okada, O. Ishizuka, S. Ozono, M. Gotoh, T. Sugiyama, N. Seki, M. Yoshida, S. Yamada, Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J. Urol. 186, 170–174 (2011)CrossRefPubMedGoogle Scholar
- 38.K. Torimoto, A. Hirayama, C. Matsushita, Y. Matsumoto, A. Yamada, K. Fujimoto, Y. Hirao, Evaluation of sleep quantity and quality in older adults with nocturia using portable electroencephalogram acquisition device. Neurourol. Urodyn. 31, 982–983 (2012)Google Scholar
- 46.H. Nakagawa, K. Niu, A. Hozawa, Y. Ikeda, Y. Kaiho, K. Ohmori-Matsuda, N. Nakaya, S. Kuriyama, S. Ebihara, R. Nagatomi, I. Tsuli, Y. Arai, Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J. Urol. 184, 1413–1418 (2010)CrossRefPubMedGoogle Scholar